Trending...
- SecureDose Introduces a Smarter Approach to Medication Management
- Mini On-Line Creative Getaways in August and September
- Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
New preclinical research reports that HuMOLYTE®, a magnesium-containing medical food with 2′-fucosyllactose, reduced chemotherapy-induced gastrointestinal and oral mucosal injury in Wistar rats
SACRAMENTO, Calif. - illiNews -- IGH Naturals announced that a peer-reviewed original research study evaluating HuMOLYTE® has been accepted and published in Frontiers in Nutrition. The study, titled "Supplementation with 2′-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats," reports preclinical findings on HuMOLYTE®, a medical food formulated with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on illi News
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on illi News
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on illi News
- Flexlid Introduces an Expandable, Multipurpose Approach to Kitchen Sink Coverage
- Mayor Brandon Johnson Signs Executive Order Creating Enhanced Regulatory Review for Data Centers in Chicago and Calls for a Temporary Data Center Moratorium
- Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
- Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
- Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on illi News
- Tube N Grow Introduces an Integrated Approach to Vertical Home Gardening
- Chicago: Mayor Brandon Johnson Announces Appointment of Ashlee Gabrysch as Chief Financial Officer
- Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
- The Kryder Law Group, LLC Announces $500,000 Recovered in Slip and Fall Settlements
- Contracting Resources Group Named to Inc. 5000 for the Ninth Time
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Source: IGH Naturals
Filed Under: Health
0 Comments
Latest on illi News
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
- Midwest Stratospheric Data Systems Announces Limited Partnership Under Aerostratospheric
- The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
- Chicago: ICYMI: Mayor Brandon Johnson Cuts Ribbon on Two Englewood Homes Newly Rehabilitated Through Rebuild 2.0
- Chicago: Mayor Brandon Johnson, CTA Celebrate Reopening of a Fully Accessible Austin Green Line Station
- Midwest Stratospheric Data Systems Receives 2026 Global Recognition Award for research
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
- Digi 995: The Prime Nexus Sends Robot Heroes Into a Deadly Network of Game Worlds
- Chicago: Mayor Brandon Johnson Joins UCAN for REACH 21 Milestone Celebration, Honoring Achievements of Youth Engaged in Violence Prevention Programming
- Mini On-Line Creative Getaways in August and September
- Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
- Chicago: Mayor Brandon Johnson, DCASE Complete Installation Of "Other Washingtons" Public Artwork at the George Washington Monument
- Litera Awarded Customer Intelligence Platform of the Year in 2026 MarTech Breakthrough Awards
- Black Ribbon Productions Launches With Fearless 2026 Horror Slate
- Actor Dominic Pace Returns to Television and Film
- Attorney General Raoul, City of Chicago Sue Pullman Innovations Over Air Pollution and Excessive Odors
- Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services
- Silicon Box Ships 500M Units at High Yield, Expands Production Capacity for Panel-Level Packaging
